CClinicalTrials.gg
CompletedNCT03144752Updated Jul 19, 2019

Optimizing Clinical Screening and Management of Maternal Mental Health: Predicting Women at Risk for Perinatal Depression

An observational study in Depression, sponsored by Janssen Research & Development, LLC. Completed at 1 site in United States. Open to female participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-19.

Sponsored by Janssen Research & Development, LLC · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
298
Ages
18 Years to 44 Years
Sex
Female
01

Study summary

The purpose of this study is to determine if medical, biological, psychological, and social risk factors can be used to develop algorithms that will predict perinatal depression (PND). Data capture will include baseline participant medical, psychological and family history, blood biomarkers, and psychosocial assessments.

02

Conditions studied

03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.

This study's enrollment of 298 is above the median of 160 across 1,084 observational studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 912 studies on the registry; 76 are open to participants now.

Of its 278 completed or terminated interventional studies of FDA-regulated products, 131 (47%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Approximately 300 pregnant women seeking maternal healthcare services in a department of Obstetrics and Gynecology at the University of North Carolina health center will be observed for perinatal depression.

Inclusion criteria

  • Participants must be English-speaking and able to understand and follow clinician/researcher/provider recommendations
  • Participants must be able to read and comprehend written communications (English) and physically able to complete electronic patient-reported outcome (ePRO) assessments
  • Participants must have access to a personal smartphone or a computer and an active personal email address for which they are willing to use for data collection
  • Each participant must sign an informed consent form (ICF) indicating that she understands the purpose of and procedures required for this study and is willing to participate in and comply with all procedures in the study
  • Participant must be willing and able to have blood draws and to complete the self-reported assessments via mobile electronic device during the study

Exclusion criteria

Exclusion Criteria:

  • Participant is not English speaking
  • Lifetime mood disorder other than major depressive disorder (MDD) (example [e.g.], bipolar I) or anxiety disorder
  • Lifetime psychotic disorder (eg, schizophrenia, schizoaffective disorder)
  • Lifetime alcohol or illicit substance dependence (moderate-severe)
  • Current Post-traumatic Stress Disorder (PTSD), significant alcohol or illicit drug use (Ethanol [ETOH]/nonprescription drug use) within 12 months greater than or equal to (>=)occasional use
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
298 participants (actual)
Patient registry
No

Groups and cohorts

  • Cohort 1: Participants between 8 to 14 weeks gestation

    Cohort 1 will include female participants who present for the first prenatal visit which takes place between Weeks 8 and 14 at maternity practices associated with University of North Carolina (UNC) Women's Care. Biomarkers, medical and psychiatric history, and psychosocial measures will be evaluated and utilized in developing a predictive risk algorithm for perinatal depression.

  • Cohort 2: Participants between 15 to 36 weeks gestation

    Cohort 2 will include female participants enrolled at various points in their pregnancy from Week 15 up through 36 weeks gestation. Biomarkers, medical and psychiatric history, and psychosocial measures will be evaluated and utilized in developing a predictive risk algorithm for perinatal depression.

06

What researchers measure

Primary outcomes

  1. Biomarker Assessment for Perinatal Depression

    Blood samples will be collected to evaluate biomarkers for perinatal depression.

    Time frame: Up to Visit 3 (Weeks 36-40 of gestation)

  2. Medical and Psychiatric History

    Participants will be asked to complete medical and psychiatric history questionnaire during their 1st visit.

    Time frame: Visit 1 (anywhere between Weeks 8-36 of gestation)

  3. Maternity Social Support Scale (MSSS) Score

    This is a brief 6 item questionnaire used a 5 level Likert type scale to assess perceived social support during the prenatal period. The score on each item within this scale (ranging from 1 to 5) is summarized according to the origin of support (eg, support from family/friends and support from partner). The total score is 30 with classified social support in to three categories; high social support (for scores 24-30), medium social support (18-23) and low social support (below 18) categories. High total score indicates increased perceived support.

    Time frame: Up to 24-26 weeks postpartum

  4. Edinburgh Postnatal Depression Scale (EPDS)

    The EPDS is a self-administered scale that indicates how the mother has felt during the previous week. The scale consists of 10 questions. Responses are scored 0, 1, 2, or 3 according to increased severity of the symptom. The total score is determined by adding together the scores for each of the 10 items. The EPDS total score ranges from 0 to 30. A score of greater than (\>)9 is indicative of perinatal major depression.

    Time frame: Up to 24-26 weeks postpartum

  5. Perceived Stress Scale (PSS)

    The Perceived Stress Scale (PSS) measures the degree to which situations in one's life are appraised as stressful. The questionnaire asks the client about their perceived stress and their feelings and thoughts during the last month. The scale has ten questions asking respondents to circle a number between 0 and 4: 0 = Never, 1 = Almost Never, 2 = Sometimes, 3 = Fairly Often and 4 = Very Often. The range of possible score is from 0 to 40. Scores around 13 are considered average. Scores of 20 or higher are considered to be indicative of high stress levels.

    Time frame: Up to 24-26 weeks postpartum

  6. State-trait Anxiety Inventory (STAI)

    The State-Trait Anxiety Inventory (STAI) is a measure of trait and state anxiety. STAI contains 20 items for assessing trait anxiety and 20 items for state anxiety. State anxiety items include: "I am tense; I am worried" and "I feel calm; I feel secure." Trait anxiety items include: "I worry too much over something that really doesn't matter" and "I am content; I am a steady person." All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). Scores may range from 20 to 80 with higher scores indicating greater state anxiety.

    Time frame: Up to 24-26 weeks postpartum

  7. Obsessive Compulsive Inventory - Revised (OCI-R)

    The OCI-R, a shortened version of the Obsessive-Compulsive Inventory, assesses symptoms of Obsessive Compulsive Disorder (OCD). The measure consists of 18 items (e.g. "I frequently have get nasty thoughts and have difficulty in getting rid of them"). On a five point scale, respondents rate how distressed or bothered they have been in the past month by the symptom described, with responses ranging from "Not at all" to "Extremely." Scores are generated by adding the item scores. Total possible score range 0 to 72, scores at or above 21 indicating the likely presence of OCD.

    Time frame: Up to 24-26 weeks postpartum

  8. Patient-Reported Outcomes Measurement Information System (PROMIS)- Pain Interference

    Self-reported changes in the levels of pain as measured by the PROMIS Pain Interference Scale. PROMIS-PI scores provided substantial information across levels of pain. The scale for adults in the general population is available in both a 41 item long-form computer adaptive version and a 4 item short form which will be used in this study. Each item is based on experiences in the last seven days before administering the questionnaire. It uses a 5-point rating scale (1-"not at all" to 5-"very much"), with higher scores indicating more pain interference.

    Time frame: Up to 8-9 weeks postpartum

  9. PROMIS-Sleep Disturbance

    The PROMIS-Sleep Disturbance (PROMIS-SD) is used to asses self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS- SD includes 27 with each item is based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 8 item short form will be used in this study, in which responses are scored 1 to 5 for each item. A higher score on 5 of the 8 items reflects a worse outcome, whereas a higher score on 3 items reflects an improved outcome; therefore, the directionality of the 8 item scores are first synchronized prior to calculation of the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 8-item form, the lowest possible raw score is 8; the highest possible raw score is 40. PROMIS scores are presented as T-scores. Higher T-scores represent more of the concept being measured (sleep disturbance).

    Time frame: Up to 24-26 weeks postpartum

  10. PROMIS-Sleep Related Impairment

    The Patient Reported Outcomes Measurement Information System (PROMIS)Sleep Related Impairment bank is a 16 item computer adaptive test bank that focuses on perceptions of alertness, sleepiness, and tiredness during usual waking hours. Each item is based on a seven day recall period and assessed on a 5 score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 8-item form, the lowest possible raw score is 8; the highest possible raw score is 40. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the 8-item form, the lowest possible raw score is 8; the highest possible raw score is 40. PROMIS scores are presented as T-scores. Higher T-scores represent more of the concept being measured (sleep related impairment).

    Time frame: Up to 24-26 weeks postpartum

  11. PROMIS-Self Efficacy

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Self-Efficacy for Managing Emotions is designed for adults with at least 1 chronic health condition. The items are not focused on one specific condition but are designed to universally measure one's current level of confidence to manage emotional symptoms such as anxiety, depression, helplessness, discouragement, frustration, disappointment and anger. The instrument has a 25 item computer adaptive test form and 2 short forms: an 8 item and a 4 item. Each question has 5 response options ranging in value from 1 to 5. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the 8-item form, the lowest possible raw score is 8; the highest possible raw score is 40. PROMIS scores are presented as T-scores. Higher T-scores represent more of the concept being measured (self efficacy).

    Time frame: Up to 24-26 weeks postpartum

  12. Patient Health Questionnaire-2 (PHQ-2)

    The Patient Health Questionnaire-2 (PHQ-2) is a 2-item Brief Depression Screening Instrument. It inquires about the frequency of depressed mood and anhedonia over the past 2 weeks, scoring each as 0 ("not at all") to 3 ("nearly every day"). It ranges from 0-6, where higher score means higher depressive symptoms.

    Time frame: Up to 24-26 weeks postpartum

  13. Perinatal Post-traumatic Stress Disorder (PTSD) Questionnaire - Modified (PPQ)

    The Perinatal Post-Traumatic Stress Disorder (PTSD) Questionnaire (PPQ) is a 14-item measure assessing post-traumatic symptoms related to the childbirth experience, including intrusiveness or re-experiencing, avoidance behaviors and hyperarousal or numbing of responsiveness. The PPQ also contains one item pertaining to feelings of guilt. Response options were modified from the original dichotomous scale to a five-level likert scale (scored 0 to 4). Mothers were instructed to provide responses that reflected their experience during the targeted time frame (4 to18 months postpartum). The total possible score on the modified PPQ ranged from 0 to 56. A score of 19 or higher on the PPQ indicates clinically significant distress that merits referral of the mother to a mental health care professional.

    Time frame: At 12-14 weeks postpartum

  14. Generalized Anxiety Disorder-7 (GAD-7)

    The GAD-7 is a self-reported questionnaire for screening and measurement of severity of generalized anxiety disorder (GAD). This questionnaire has 7 items which measure the severity of various signs of GAD over the past 2 weeks according to the reported response categories with assigned points - "not at all" (0 points), "several days" (1 point), "more than half the days" (2 points), and "nearly every day" (3 points). Total score=sum of all 7 items; ranges from 0 to 21; Higher score=greater level of anxiety).

    Time frame: Up to 24-26 weeks postpartum

  15. Pregnancy-Unique Quantification of Emesis and Nausea - Modified (PUQE)

    The modified version of the Pregnancy-Unique Quantification of Emesis and Nausea (modified-PUQE) provides global nausea and vomiting of Pregnancy (NVP) severity index. The modified-PUQE is a three-item questionnaire with each item having a 5 level Likert type scale (1 to 5, increasing in severity). The total score is the sum of replies to the 3 items and rated from 3 (no symptoms) to 15 (most severe). A score of 7 to 12 indicates moderate NVP and a score greater than 13 indicates severe NVP.

    Time frame: Up to 24-25 weeks

  16. Infant Feeding Intentions Scale (IFI)

    The Infant Feeding Intentions (IFI) scale was developed to meet the need in breastfeeding behavior studies for quantitative measure of maternal breastfeeding intentions. This is a 5 item scale that probes strength of intentions to initiate breastfeeding. Total score ranges from 0 to 16. Higher score means higher intention to breastfeed exclusively.

    Time frame: At 24-25 weeks

  17. Neonatal Breastfeeding Questionnaire

    The questions used to assess breastfeeding behavior immediately post-delivery are adapted from Infant Feeding Practices Study II (IFPS II). The Neonatal Questionnaire was sent to the mother when her infant is approximately 3 weeks old. This questionnaire examined factors that commonly occur near the time of the birth and that affect infant feeding choices. This study will use 3 of their face valid questions to assess if the new mother has tried to breastfeed, if so, how long it took for her milk to produce, and if she is still breastfeeding.

    Time frame: At 5-9 days postpartum

  18. Postnatal Breastfeeding Questionnaire

    The questions used to assess longitudinal breastfeeding behavior post-delivery are also adapted from Infant Feeding Practices Study II (IFPS II). The Postnatal Questionnaires consist of various combinations of 8 modules that were mailed to the mother approximately monthly from the time her infant is 2 months through 12 months of age. A 4 question subset of the breastfeeding questionnaire will be used in this study to evaluate continued breastfeeding practices and reasons to begin using formula or to stop breastfeeding.

    Time frame: At 24-26 weeks postpartum

Secondary outcomes

  1. Incidence of Perinatal Depression (PND)

    Incidence of PND will be assessed at different time points, including those participants who are already depressed at baseline and both antenatal and postpartum depression onset in a real world population of pregnant women seeking health care.

    Time frame: Up to 60 weeks

07

Study locations

1 site
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03144752
Lead sponsor
Janssen Research & Development, LLC
Responsible party
Sponsor
First posted
May 9, 2017
Start date
Apr 14, 2017
Primary completion
May 5, 2019
Completion
May 5, 2019
Last update
Jul 19, 2019

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion